9 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $277M | -$59M | 74.2% | -20.6% | -$49M | $131M | $70M |
| 2024 | $179M | -$159M | 59.7% | -90.8% | -$99M | $133M | $48M |
| 2023 | $170M | -$225M | 55.6% | -133.3% | -$167M | $131M | $65M |
| 2022 | $185M | -$200M | 68.7% | -108.0% | -$200M | $125M | $90M |
| 2021 | $154M | -$207M | 68.1% | -135.4% | -$254M | — | $139M |
| 2020 | $98M | -$146M | 77.1% | -155.3% | -$168M | — | $123M |
| 2019 | $85M | -$69M | 73.8% | -92.1% | $194M | — | $97M |
| 2018 | $56M | -$46M | 64.7% | -89.4% | -$39M | — | $55M |
| 2017 | $38M | -$43M | 59.2% | -115.7% | -$37M | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $71M | -$20M | 73.6% | -27.1% | -$10M | $131M | $78M |
| Dec '25 | $72M | -$14M | 74.6% | -17.8% | $1M | $131M | $70M |
| Sep '25 | $94M | $10M | 80.7% | 10.9% | -$8M | $132M | $55M |
| Jun '25 | $59M | -$26M | 69.4% | -42.5% | -$13M | $134M | $43M |
| Mar '25 | $52M | -$30M | 67.6% | -56.4% | -$30M | $134M | $51M |
| Dec '24 | $47M | -$34M | 62.0% | -71.3% | -$13M | $133M | $48M |
| Sep '24 | $46M | -$32M | 64.1% | -70.3% | -$27M | $133M | $38M |
| Jun '24 | $43M | -$46M | 55.3% | -109.6% | -$19M | $132M | $60M |
| Mar '24 | $42M | -$48M | 56.9% | -116.5% | -$40M | $132M | $71M |
| Dec '23 | $46M | -$69M | 57.2% | -155.2% | -$28M | $131M | $65M |
| Sep '23 | $38M | -$50M | 49.0% | -134.4% | -$49M | $130M | $89M |
| Jun '23 | $49M | -$48M | 63.4% | -97.7% | -$27M | — | $109M |
| Mar '23 | $38M | -$58M | 50.4% | -151.9% | -$62M | — | $95M |
| Dec '22 | $55M | -$40M | 69.9% | -71.0% | -$33M | $125M | $90M |
| Sep '22 | $48M | -$45M | 68.8% | -95.0% | -$48M | — | $218M |
| Jun '22 | $44M | -$52M | 69.7% | -120.3% | -$52M | — | $76M |
| Mar '22 | $39M | -$63M | 65.8% | -163.3% | -$68M | — | $115M |
| Dec '21 | $38M | -$61M | 62.2% | -162.4% | -$63M | — | $139M |
| Sep '21 | $39M | -$56M | 64.0% | -142.7% | -$58M | — | $122M |
| Jun '21 | $39M | -$49M | 72.0% | -129.2% | -$59M | — | $184M |
How the market has priced ADPT against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Adaptive Biotechnologies Corp's revenue has grown 23.0% per year. These are computed facts, not advice.
As of FY2025, Adaptive Biotechnologies Corp reported $131M of total debt against $70M of cash; operating income covered interest expense -4.8×.
In FY2025, gross margin was 74.2%, operating margin -20.6%, and net margin -21.5%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.